News Headlines Article

First drug specifically for postpartum depression is approved
The Washington Post

The Food and Drug Administration on Tuesday approved the first drug specifically for postpartum depression — a debilitating condition that affects hundreds of thousands of women a year in the United States.

The disorder, which begins during pregnancy or within a month of childbirth, is characterized by feelings of worthlessness or guilt, or thoughts of suicide and is far more severe than the common “baby blues.” The condition can interfere with a mother’s ability to bond with an infant, which can affect the baby’s development. An estimated 400,000 women in the United States each year suffer from postpartum depression.

The newly approved drug, called brexanolone, will be marketed under the name Zulresso. It will cost, on an average, $34,000 per patient for a course of treatment, before discounts, according to the manufacturer, Sage Therapeutics in Cambridge, Mass.